Please login to the form below

Not currently logged in


This page shows the latest idebenone news and features for those working in and with pharma, biotech and healthcare.

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone).

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...